Core Viewpoint - Beida Pharmaceutical (300558.SZ) reported a revenue of 1.731 billion yuan for the first half of the year, reflecting a year-on-year growth of 15.37%, while the net profit attributable to shareholders decreased by 37.53% to 140 million yuan [1] Financial Performance - The company's operating revenue reached 1.731 billion yuan, marking a 15.37% increase compared to the previous year [1] - The net profit attributable to shareholders was 140 million yuan, which represents a significant decline of 37.53% year-on-year [1] - The net profit excluding non-recurring gains and losses was 190 million yuan, showing a decrease of 11.97% compared to the same period last year [1]

智通财经APP讯，贝达药业(300558.SZ)发布2025年半年度报告，该公司营业收入为17.31亿元，同比增 长15.37%。归属于上市公司股东的净利润为1.4亿元，同比减少37.53%。归属于上市公司股东的扣除非 经常性损益的净利润为1.91亿元，同比减少11.97%。基本每股收益为0.33元。 ...

贝达药业（SZ 300558，收盘价：70.21元）8月19日晚间发布半年度业绩报告称，2025年上半年营业收 入约17.31亿元，同比增加15.37%；归属于上市公司股东的净利润约1.4亿元，同比减少37.53%；基本每 股收益0.33元，同比减少38.89%。 （文章来源：每日经济新闻） ...

贝达药业股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算 | 2025 年期初占用 | 2025 年半年度占用累 | 2025 年半年度占用 | 2025 年半年度偿 | 2025 年半年度期 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 的会计科目 | 资金余额 | 计发生金额（不含利息） | 资金的利息(如有) | 还累计发生金额 | 末占用资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | | 小计 | | | | | ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-055 贝达药业股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司 自律监管指南第 2 号——公告格式》等有关规定，贝达药业股份有限公司（以下 简称"公司"）就 2025 年半年度募集资金存放与使用情况作如下专项报告： 一、 募集资金基本情况 (一) 实际募集资金金额、资金到位情况 1、 首次公开发行股票募集资金到位情况 经中国证券监督管理委员会以证监许可[2016]2350 号文《关于核准贝达药 业股份有限公司首次公开发行股票的批复》核准，获准向社会公开发行人 民币普通股（A 股）4,100.00 万股，每股面值 1 元，发行价格 17.57 元/股， 募集资金总额为 720,370,000.00 元，扣除承销商发行费用 48,000,000.00 元后的募集资金为人民币 672,370,000 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-052 贝达药业股份有限公司 二、监事会会议审议情况 1、会议审议并通过了《2025 年半年度报告全文及摘要》 第四届监事会第二十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席张洋南先生召集，会议通知于 2025 年 8 月 8 日 以电子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2025 年 8 月 19 日在公司杭州总部 3 楼会议室召开，采取现 场会议和电话会议相结合的方式，现场投票表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席张洋南先生主持，公司证券事务代表沈剑豪先 生列席了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》的有关规定。 经审核，监事会认为董事会编制和审议公司《2025 年半年度报告全文及摘要》 的程序符合 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-051 贝达药业股份有限公司 第四届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次董事会于 2025 年 8 月 19 日在公司杭州总部行政大楼十五楼会议室召 开，采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 12 人，实际出席会议人数 12 人。 4、本次董事会由董事长丁列明先生主持，公司董事会秘书吴灵犀先生列席 了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、会议审议并通过了《2025 年半年度报告全文及摘要》 经审议，董事会认为公司《2025 年半年度报告》及《2025 年半年度报告摘要》 的编制和审核程序符合相关法律法规及中国证券监督管理委员会、深圳证券交易 所有关规定的要求，报告内容真实、准确、完整地反映了公司 2025 年上半年的 财务状况和经营成果，不存在虚假记载、误导性陈述或重大遗漏。 公司董事会审计委员会已于 ...

贝达药业股份有限公司 2025 年半年度报告全文 +贝达药业股份有限公司 2025 年半年度报告 【披露时间】 1 | 第一节 | 重要提示、目录和释义 | 1 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 4 | | 第三节 | 管理层讨论与分析 | 6 | | 第四节 | 公司治理、环境和社会 | 35 | | 第五节 | 重要事项 | 37 | | 第六节 | 股份变动及股东情况 | 41 | | 第七节 | 债券相关情况 | 46 | | 第八节 | 财务报告 | 47 | 贝达药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计 主管人员)王铁奇声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承 ...

Core Viewpoint - The recent decline in the innovative drug ETF (159622) is seen as a short-term correction, with expectations of continued growth driven by liquidity and upcoming catalysts such as potential interest rate cuts by the Federal Reserve [1][2][3] Group 1: Market Performance - The innovative drug ETF experienced a decline of over 1.5%, with significant stock performance divergence among its components, including gains from companies like Ganli Pharmaceutical (+7%) and Enhua Pharmaceutical (+5%) [1] - The overall market sentiment remains bullish, with a strong rotation and inflow of capital into innovative drug ETFs during corrections [1] Group 2: Catalysts for Growth - The innovative drug sector is expected to benefit from a liquidity-driven market, particularly with anticipated interest rate cuts from the Federal Reserve, which would lower financing costs for drug companies [1][2] - The sector has seen over $2.5 billion in upfront payments for external licensing agreements in the first half of the year, indicating strong ongoing interest and potential for future growth [2] Group 3: Policy Support - Recent updates from the National Healthcare Security Administration regarding the 2025 national medical insurance drug list and commercial insurance innovative drug list show strong support for innovative drugs, including CAR-T therapies and other cancer treatments [3] Group 4: Future Outlook - The upcoming global pharmaceutical conferences and the expected release of key clinical data are anticipated to provide further momentum for the innovative drug sector [5] - The potential for continued high levels of external licensing agreements and the expiration of patents for significant drugs by 2030 suggest a robust pipeline for Chinese innovative drugs [2][5]

Group 1: Core Insights - The report highlights a strong performance in the pharmaceutical and biotechnology sector, with an overall increase of 3.08% from August 11 to August 15, 2025, outperforming the CSI 300 index by 0.71 percentage points [5][6] - Year-to-date, the pharmaceutical and biotechnology sector has risen by 25.02%, ranking fourth among 31 industries, and surpassing the CSI 300 index by 18.22 percentage points [5][6] - The current PE valuation for the pharmaceutical and biotechnology sector stands at 31.31 times, which is at the historical median level, with a premium of 145% compared to the CSI 300 index [5][6] Group 2: Industry Developments - The National Healthcare Security Administration (NHSA) announced the preliminary review list for the 2025 National Basic Medical Insurance and commercial insurance drug directories, with 534 drugs passing the basic medical insurance review and 121 passing the commercial insurance review [6][7] - The NHSA issued a temporary management method for disease-based payment, aimed at addressing issues such as dynamic adjustment expectations and regional management disparities [6][7] - Novo Nordisk received FDA approval for a supplemental new drug application for semaglutide (Wegovy) to treat patients with metabolic dysfunction-associated fatty liver disease [7] Group 3: Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector is expected to continue its upward trend, driven by the recent announcements from the NHSA regarding drug directory updates and payment management reforms [7] - It is recommended to focus on investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services as the market enters a period of intensive mid-year report disclosures [7][9] - A specific stock recommendation list includes companies such as Betta Pharmaceuticals, Teva Biologics, and Kaili Medical, with a watchlist including Kelun Pharmaceutical and Qianhong Pharmaceutical [9]